title: [Circadian rhythm in susceptibility of mice to the anti-tumor drug carboplatin].
abstract: The platinum-containing compounds has become a major chemical agent in the treatment of cancer. A circadian rhythm in the susceptibility of rodents and human being to cisplatin has been demonstrated, the maximal tolerance being found in the animal's active phase. Carboplatin is a second generation analog. Two studies were performed on mice with carboplatin under 12:12 light dark cycle to study its chronotoxicity and chronoeffectiveness. In study I, single intraperitoneal injection of 192mg/kg (LD50) carboplatin was given to four groups of mice at four different circadian stage. It was found that at 50% the overall mortality of mice, there was a mortality difference of 28% for mice receiving the drug at 9 a.m. to 71% for mice receiving drug at 9 p.m. It demonstrated that carboplatin was better tolerated in the animal's early sleep phase. In study II, S180 tumor-bearing mice were treated with 50mg/kg of carboplatin. The longest mean survival time and the lowest marrow toxicity occurred in the group which received the drug at the beginning of the sleep phase. It showed that the susceptibility of mice to carboplatin is circadian stage dependent. These data clearly demonstrate that, by timing the administration of drugs according to body rhythms, such as the host susceptibility-resistance rhythm to a drug, one can gain a therapeutic advantage over an approach which ignores such rhythms.
authors.affiliation: Affiliated Hospital of Shan dong Medical University, Jinan.
authors.forename: X H
authors.initials: XH
authors.lastname: Lu
authors.forename: L J
authors.initials: LJ
authors.lastname: Yin
mesh_terms: D000818:Animals; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000633:toxicity; D002940:Circadian Rhythm; D008297:Male; D051379:Mice; D012510:Sarcoma 180 / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D016190:Carboplatin